SEC Form 4 · accession 0001209191-17-036969
Ultragenyx Pharmaceutical Inc. · RARE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
John Richard Pinion
Officer — See Remarks
Period of report
Jun 1, 2017
Accepted (ET)
Jun 1, 2017 · 9:11 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001515673
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | Jun 1, 2017 | F | 282 | $56.61 | D | 12,588 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Represents shares surrendered to the Issuer by the Reporting Person to pay required tax withholdings due to the vesting of Restricted Stock Units.
- F2Includes 375 shares acquired under the Company's 2014 Employee Stock Purchase Plan on April 28, 2017.
Remarks
EVP and Chief Quality Operations Officer